- Recombinant Agalsidase Beta
Agalsidase Beta BS I.V. Infusion [JCR]NEW
- Agalsidase Beta BS I.V. Infusion [JCR] is launched in November 2018 as a biosimilar for agalsidase beta for the treatment of Fabry disease, a type of lysosomal storage disorders (LSDs). This product is not only JCR’s first enzyme replacement therapy (ERT) for LSDs, but also the first domestic ERT product for LSDs.
- ・ Fabry disease